Arvinas (ARVN) said Friday that data from the first-in-human clinical trial of ARV-102 demonstrated substantial reduction of leucine-rich repeat kinase 2, or LRRK2, a multifunctional protein that has been primarily implicated in Parkinson's disease.

ARV-102 was generally safe and well tolerated with no serious adverse events reported after single or multiple doses, the company said.

At a single oral dose of at least 60 mg, and once daily repeated oral doses of at least 20 mg, ARV-102 achieved greater than 50% LRRK2 reduction in the cerebral spinal fluid and greater than 90% LRRK2 reduction in the peripheral blood mononuclear cells.

The company said its findings support continued evaluation of ARV-102 in neurodegenerative diseases associated with LRRK2 dysfunction and a phase 1 trial in patients with Parkinson's disease has been initiated and is currently enrolling.